Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATGross ProfitLeasesLong-Term Debt IssuancesLong-Term Debt RepaymentsMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetShares IssuedShares OutstandingShares Outstanding
Ratios

Karyopharm Therapeutics (KPTI) Cost of Revenue (2019 - 2025)

Karyopharm Therapeutics' Cost of Revenue history spans 6 years, with the latest figure at $1.6 million for Q4 2025.

  • For Q4 2025, Cost of Revenue rose 44.66% year-over-year to $1.6 million; the TTM value through Dec 2025 reached $5.9 million, up 6.18%, while the annual FY2025 figure was $5.9 million, 2.92% up from the prior year.
  • Cost of Revenue reached $1.6 million in Q4 2025 per KPTI's latest filing, down from $2.1 million in the prior quarter.
  • In the past five years, Cost of Revenue ranged from a high of $2.1 million in Q3 2025 to a low of $589000.0 in Q3 2021.
  • Average Cost of Revenue over 5 years is $1.3 million, with a median of $1.2 million recorded in 2023.
  • Peak YoY movement for Cost of Revenue: surged 151.75% in 2022, then crashed 40.26% in 2023.
  • A 5-year view of Cost of Revenue shows it stood at $742000.0 in 2021, then soared by 151.75% to $1.9 million in 2022, then plummeted by 40.26% to $1.1 million in 2023, then fell by 1.08% to $1.1 million in 2024, then surged by 44.66% to $1.6 million in 2025.
  • Per Business Quant, the three most recent readings for KPTI's Cost of Revenue are $1.6 million (Q4 2025), $2.1 million (Q3 2025), and $1.0 million (Q2 2025).